πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

951 results for β€œEli” Clear

  1. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  2. CT-95

    Context Therapeutics

    Mesothelin-Expressing Tumors

    phase 1 small molecule active

    1 trial

  3. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  4. Cemiplimab

    Regeneron UK Limited

    Epithelial Ovarian Cancer

    phase 1 small molecule active

    1 trial

  5. Clarithromycin

    Takeda

    Helicobacter Pylori

    phase 1 small molecule completed

    2 trials

  6. Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

    BioNTech SE

    Advanced non-small cell lung cancer

    phase 1 other active

    1 trial

  7. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  8. Dasatinib

    United Therapeutics Europe Ltd

    Malignant Pleural Mesothelioma

    phase 1 small molecule completed

    1 trial

  9. Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)

    Disc Medicine

    Adult patients diagnosed with resectable epithelioid MPM, following first-line chemotherapy.

    phase 1 other active

    1 trial

  10. ELI-002 2P

    Elicio Therapeutics

    Minimal Residual Disease

    phase 1 small molecule completed

    1 trial

  11. EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers

    Eli Lilly Co.

    Breast Cancer, Endometrial cancer

    phase 1 other active

    1 trial

  12. Effect of Erythromycin on the absorption, metabolism and elimination of CHF6001 in healthy volunteers

    Chiesi Farmaceutici S.p.A

    This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.

    phase 1 other active

    1 trial

  13. Elimusertib (BAY1895344)

    Bayer HealthCare AG

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  14. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  15. First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

    Advanced Accelerator Applications

    Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy

    phase 1 other active

    1 trial

  16. GB-4362

    Generate Biomedicines

    Advanced Urothelial Cancer

    phase 1 small molecule active

    1 trial

  17. Gonadorelin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 other completed

    1 trial

  18. Human Amniotic Epithelial Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  19. Human amniotic epithelial stem cells（hAESCsοΌ‰

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 1 mab terminated

    1 trial

  20. INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

    Disc Medicine

    Patients with malignant peritoneal mesothelioma

    phase 1 other active

    1 trial

  21. ION356

    IONIS PHARMACEUTICALS INC

    Pelizaeus-Merzbacher Disease

    phase 1 small molecule active

    1 trial

  22. In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  23. Insulin Peglispro

    Eli Lilly and Company

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  24. Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

    Lacuna Pharma Pty Ltd

    Geographic Atrophy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources